<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1302233244
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DABITRAN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DABIGATRAN ETEXILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        110
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        250.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AE07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dabigatran Etexilate Capsules 110mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dabigatran Etexilate Capsules 110mg 
Each capsule contains Dabigatran etexilate Mesylate equivalent to 110mg of Dabigatran    etexilate. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Capsule 
Dabigatran Etexilate Capsules 110mg 
Cream opaque cap / Cream opaque body size ‘1’ HPMC capsules imprinted with ‘H’ on cap and ‘D16’ on body with black ink, filled with mixture of off white to yellowish white pellets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology&nbsp; Primary Prevention of Venous Thromboembolism in Orthopaedic Surgery (pVTEp orthopaedic surgery)&nbsp;</p><p>Patients following elective knee replacement surgery&nbsp;</p><p>The recommended dose of Dabigatran Etexilate Capsules is 220 mg once daily taken as 2 capsules of 110 mg. Treatment should be initiated orally within 1&ndash;4 hours of completed surgery with a single of 110 mg capsule and continuing with 2 capsules once daily thereafter for a total of 10 days.</p><p>Patients following elective hip replacement surgery&nbsp;</p><p>The recommended dose of Dabigatran Etexilate Capsules is 220 mg once daily taken as 2 capsules of 110 mg. Treatment should be initiated orally within 1&ndash;4 hours of completed surgery with a single capsule of 110 mg and continuing with 2 capsules once daily thereafter for a total of 28-35 days.</p><p>For the following groups the recommended daily dose of Dabigatran Etexilate Capsules is 150 mg taken once daily as 2 capsules of 75 mg.</p><p>Treatment should be initiated orally within 1-4 hours of completed surgery with a single capsule of 75 mg and continuing with 2 capsules once daily thereafter for a total of 10 days (knee replacement surgery) or 28-35 days (hip replacement surgery):</p><p>&bull;&nbsp; Patients with moderate renal impairment (creatinine clearance, CrCL 30-50 mL/min) [see Renal impairment (pVTEp orthopaedic surgery)]&nbsp;</p><p>&bull;&nbsp; Patients who receive concomitant verapamil, amiodarone, quinidine [see Concomitant use of Dabigatran Etexilate Capsules with mild to moderate P-glycoprotein (P-gp) inhibitors, i.e.</p><p>amiodarone, quinidine or verapamil (pVTEp orthopaedic surgery)]</p><p>&bull;&nbsp; Patients aged 75 or above [see Elderly (pVTEp orthopaedic surgery)]</p><p>For both surgeries, if haemostasis is not secured, initiation of treatment should be delayed. If treatment is not started on the day of surgery then treatment should be initiated with 2 capsules once daily.</p><p>Assessment of renal function (<u>pVTEp orthopaedic surgery</u>):</p><p>In all patients:</p><p>&bull;&nbsp; Renal function should be assessed by calculating the creatine clearance (CrCL) prior to initiation of treatment with Dabigatran Etexilate Capsules to exclude patients with severe renal impairment (i.e. CrCL &lt; 30 mL/min) (see sections 4.3, 4.4 and 5.2). Dabigatran Etexilate</p><p>Capsules is contraindicated in patients with severe renal impairment</p><p>&bull;&nbsp; Renal function should also be assessed when a decline in renal function is suspected during treatment (e.g. hypovolaemia, dehydration, and in case of concomitant use of certain medicinal products)</p><p>The method used to estimate renal function (CrCL in mL/min) during the clinical development of Dabigatran Etexilate Capsules was the Cockcroft-Gault method. The formula is as follows:</p><p>&bull;&nbsp; For creatinine in &mu;mol/L:</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_284" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:275.25pt;height:33.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="367" height="45" alt="" vspace="0" hspace="0" border="0" style="width:367px;height:45px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;</p><p>&bull;&nbsp; For creatinine in mg/dL:</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_317" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:231.75pt;
 height:35.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="309" height="47" alt="" vspace="0" hspace="0" border="0" style="width:309px;height:47px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" />&nbsp;</p><p>This method is recommended when assessing patients&#39; CrCL prior to and during Dabigatran Etexilate Capsules treatment.</p><p>Special populations&nbsp; Renal impairment (pVTEp orthopaedic surgery)&nbsp;</p><p>Treatment with Dabigatran Etexilate Capsules in patients with severe renal impairment (CrCL &lt; 30 mL/min) is contraindicated (see section 4.3).</p><p>In patients with moderate renal impairment (CrCL 30-50 mL/min), there is limited clinical experience. These patients should be treated with caution. The recommended dose is 150 mg taken once daily as 2 capsules of 75 mg (see sections 4.4 and 5.1).</p><p>Concomitant use of Dabigatran Etexilate Capsules with mild to moderate P-glycoprotein (P-gp) inhibitors, i.e. amiodarone, quinidine or verapamil (pVTEp orthopaedic surgery)&nbsp;</p><p>Dosing should be reduced to 150 mg taken once daily as 2 capsules of 75 mg Dabigatran Etexilate Capsules in patients who receive concomitantly dabigatran etexilate and amiodarone, quinidine or verapamil (see sections 4.4 and 4.5). In this situation Dabigatran Etexilate Capsules and these medicinal products should be taken at the same time.</p><p>In patients with moderate renal impairment and concomitantly treated with dabigatran etexilate and verapamil, a dose reduction of Dabigatran Etexilate Capsules to 75 mg daily should be considered (see sections 4.4 and 4.5).</p><p>Elderly (pVTEp orthopaedic surgery)&nbsp;</p><p>In elderly patients (&gt; 75 years) there is limited clinical experience. These patients should be treated with caution. The recommended dose is 150 mg taken once daily as 2 capsules of 75 mg (see sections 4.4 and 5.1).</p><p>As renal impairment may be frequent in the elderly (&gt;75 years), renal function should be assessed by calculating the CrCL prior to initiation of treatment with Dabigatran Etexilate Capsules to exclude patients with severe renal impairment (i.e. CrCL &lt; 30 mL/min). While on treatment the renal function should also be assessed in certain clinical situations when it is suspected that the renal function could decline or deteriorate (such as hypovolemia, dehydration, and with certain comedications, etc) (see sections 4.3, 4.4 and 5.2).</p><p>Hepatic impairment (pVTEp orthopaedic surgery)&nbsp;</p><p>Patients with elevated liver enzymes &gt; 2 upper limit of normal (ULN) were excluded in clinical trials investigating the VTE prevention following elective hip or knee replacement surgery. No treatment experience is available for this subpopulation of patients, and therefore the use of Dabigatran Etexilate Capsules is not recommended in this population (see sections 4.4 and 5.2). Hepatic impairment or liver disease expected to have any impact on survival is contraindicated (see section 4.3).&nbsp;</p><p>Weight (pVTEp orthopaedic surgery)&nbsp;</p><p>There is very limited clinical experience in patients with a body weight &lt; 50 kg or &gt; 110 kg at the recommended posology. Given the available clinical and kinetic data no adjustment is necessary (see section 5.2), but close clinical surveillance is recommended (see section 4.4).</p><p><u>Gender (pVTEp orthopaedic surgery)</u>&nbsp;</p><p>Given the available clinical and kinetic data, no dose adjustment is necessary (see section 5.2).</p><p>Switching (pVTEp orthopaedic surgery)&nbsp;</p><p>Dabigatran Etexilate Capsules treatment to parenteral anticoagulant&nbsp;</p><p>It is recommended to wait 24 hours after the last dose before switching from Dabigatran Etexilate Capsules to a parenteral anticoagulant (see section 4.5).</p><p>Parenteral anticoagulants to Dabigatran Etexilate Capsules&nbsp;</p><p>Discontinue the parenteral anticoagulant and start dabigatran etexilate 0-2 hours prior to the time that the next dose of the alternate therapy would be due, or at the time of discontinuation in case of continuous treatment (e.g. intravenous Unfractionated Heparin (UFH)) (see section 4.5).</p><p>Paediatric population (pVTEp orthopaedic surgery)&nbsp;</p><p>There is no relevant use of Dabigatran Etexilate Capsules in the paediatric population for the indication of primary prevention of venous thromboembolic events in patients who have undergone elective total hip replacement surgery or total knee replacement surgery.</p><p>Missed dose (pVTEp orthopaedic surgery)&nbsp;</p><p>It is recommended to continue with the remaining daily doses of dabigatran etexilate at the same time of the next day.</p><p>No double dose should be taken to make up for missed individual doses.</p><p>Method of administration (pVTEp orthopaedic surgery)&nbsp;</p><p>Dabigatran Etexilate Capsules can be taken with or without food. Dabigatran Etexilate Capsules should be swallowed as a whole with a glass of water, to facilitate delivery to the stomach. Patients should be instructed not to open the capsule as this may increase the risk of bleeding (see sections 5.2 and 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
•	Patients with severe renal impairment (CrCL < 30 mL/min) (see section 4.2) 
•	Active clinically significant bleeding 
•	Lesion or condition, if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities • Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin etc), heparin derivatives (fondaparinux etc), oral anticoagulants (warfarin, rivaroxaban, apixaban etc) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5) 
•	Hepatic impairment or liver disease expected to have any impact on survival 
•	Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole and dronedarone (see section 4.5) 
•	Prosthetic heart valves requiring anticoagulant treatment (see section 5.1). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hepatic impairment&nbsp;</p><p>Patients with elevated liver enzymes &gt; 2 ULN were excluded in controlled clinical trials investigating the VTE prevention following elective hip or knee replacement surgery. No treatment experience is available for this subpopulation of patients, and therefore the use of Dabigatran Etexilate Capsules is not recommended in this population.</p><p>Haemorrhagic risk&nbsp;</p><p>Dabigatran etexilate should be used with caution in conditions with an increased risk of bleeding and in situations with concomitant use of drugs affecting haemostasis by inhibition of platelet aggregation. Bleeding can occur at any site during therapy with dabigatran etexilate. An unexplained fall in haemoglobin and/or haematocrit or blood pressure should lead to a search for a bleeding site.</p><p>For situations of life-threatening or uncontrolled bleeding, when rapid reversal of the anticoagulation effect of dabigatran is required, the specific reversal agent (Praxbind, idarucizumab) is available (see section 4.9).&nbsp;</p><p>Factors, such as decreased renal function (30-50 mL/min CrCL), age &ge; 75 years, low body weight &lt; 50 kg, or mild to moderate P-gp inhibitor co-medication (e.g. amiodarone, quinidine or verapamil) are associated with increased dabigatran plasma levels (see sections 4.2, 4.5 and 5.2). The concomitant use of ticagrelor increases the exposure to dabigatran and may show pharmacodynamic interaction, which may result in an increased risk of bleeding (see section 4.5).</p><p>Use of acetylsalicylic acid (ASA), clopidogrel or non steroidal antiinflammatory drug (NSAID), as well as the presence of esophagitis, gastritis or gastroesophageal reflux increase the risk of GI bleeding. The administration of a PPI can be considered to prevent GI bleeding.</p><p>Bleeding risk may be increased in patients concomitantly treated with selective serotonin reuptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs) (see section 4.5).</p><p>Close clinical surveillance (looking for signs of bleeding or anaemia) is recommended throughout the treatment period, especially if risk factors are combined (see section 5.1). Table 1 summarises factors which may increase the haemorrhagic risk. Please also refer to contraindications in section 4.3.</p><p>Table 1: Factors which may increase the haemorrhagic risk.</p><table border="0" cellspacing="0" cellpadding="0" style="width:522px"><tbody><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Pharmacodynamic and kinetic factors</p></td><td colspan="2" style="vertical-align:top"><p>Age &ge; 75 years</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Factors increasing dabigatran plasma levels</p></td><td colspan="2" style="vertical-align:top"><p><u>Major:</u>&nbsp;</p><p>&bull; Moderate renal impairment (30-50</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>mL/min CrCL)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-gp inhibitor co-medication (some Pgp inhibitors are contraindicated, see section 4.3 and 4.5) <u>Minor:</u>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low body weight (&lt; 50 kg)</p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pharmacodynamic interactions</p></td><td colspan="2" style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASA</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NSAID</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clopidogrel</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SSRIs or SNRIs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other &nbsp; drugs &nbsp; which may &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impair haemostasis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Diseases / procedures with special haemorrhagic risks</p></td><td colspan="2" style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired coagulation disorders</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia or functional platelet defects</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recent biopsy, major trauma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial endocarditis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Esophagitis, &nbsp;&nbsp; gastritis &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or</p><p>gastroesophageal reflux</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>The presence of lesions, conditions, procedures and/or pharmacological treatment (such as</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>NSAIDs, antiplatelets, SSRIs and SNRIs, see section 4.5), which significantly increase the risk of major bleeding requires a careful benefit-risk assessment. Dabigatran Etexilate Capsules should only be given if the benefit outweighs bleeding risks.</p><p>Dabigatran Etexilate Capsules does not in general require routine anticoagulant monitoring. However, the measurement of dabigatran related anticoagulation may be helpful to avoid excessive high exposure to dabigatran in the presence of additional risk factors. The INR test is unreliable in patients on Dabigatran Etexilate Capsules and false positive INR elevations have been reported. Therefore INR tests should not be performed. Diluted thrombin time (dTT), ecarin clotting time (ECT) and activated partial thromboplastin time (aPTT) may provide useful information, but the tests are not standardised, and results should be interpreted with caution (see section 5.1).</p><p>Table 2 shows coagulation test thresholds at trough that may be associated with an increased risk of bleeding (see section 5.1)</p><p>Table 2: Coagulation test thresholds at trough that may be associated with an increased risk of</p><p>bleeding.</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_40579" o:spid="_x0000_s1026" style='width:472.5pt;height:143.8pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="60008,18261" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:rect id="Rectangle_x0020_1001" o:spid="_x0000_s1027" style='position:absolute;
  left:4800;top:654;width:15516;height:1843;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>Test (trough value)<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1002" o:spid="_x0000_s1028" style='position:absolute;
  left:16477;top:654;width:507;height:1843;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:shape id="Shape_x0020_46819" o:spid="_x0000_s1029" style='position:absolute;
  left:4556;width:91;height:289;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46820" o:spid="_x0000_s1030" style='position:absolute;
  left:4556;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_46821" o:spid="_x0000_s1031" style='position:absolute;
  left:4647;width:27560;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2756027,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l2756027,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2756027,9144"/>
 </v:shape><v:shape id="Shape_x0020_46822" o:spid="_x0000_s1032" style='position:absolute;
  left:32207;top:91;width:92;height:198;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
 </v:shape><v:shape id="Shape_x0020_46823" o:spid="_x0000_s1033" style='position:absolute;
  left:32207;width:92;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD051EtxwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pi8Iw
FMTvwn6H8Bb2pqn/ilSjuAuC4sm6h/X2aJ5tsXmpTbTdb28EweMwM79hFqvOVOJOjSstKxgOIhDE
mdUl5wp+j5v+DITzyBory6Tgnxyslh+9BSbatnyge+pzESDsElRQeF8nUrqsIINuYGvi4J1tY9AH
2eRSN9gGuKnkKIpiabDksFBgTT8FZZf0ZhRchmc5ve13622XXvO6/Z7u/q4npb4+u/UchKfOv8Ov
9lYrmMSz0Ried8IVkMsHAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPTnUS3HAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_46824" o:spid="_x0000_s1034" style='position:absolute;
  left:32299;width:22862;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2286254,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2286254,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2286254,9144"/>
 </v:shape><v:shape id="Shape_x0020_46825" o:spid="_x0000_s1035" style='position:absolute;
  left:55163;width:91;height:289;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46826" o:spid="_x0000_s1036" style='position:absolute;
  left:55163;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_46827" o:spid="_x0000_s1037" style='position:absolute;
  left:4556;top:290;width:91;height:2822;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,282245" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,282245l,282245,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,282245"/>
 </v:shape><v:shape id="Shape_x0020_46828" o:spid="_x0000_s1038" style='position:absolute;
  left:32207;top:290;width:92;height:2822;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,282245" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,282245l,282245,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,282245"/>
 </v:shape><v:shape id="Shape_x0020_46829" o:spid="_x0000_s1039" style='position:absolute;
  left:55163;top:290;width:91;height:2822;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,282245" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBP6bbrxwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/RasJA
FETfC/7DcgVfim6UVmJ0FQkK+tBC1Q+4Zq9JSPZuyK4x/n1XKPRxmJkzzGrTm1p01LrSsoLpJAJB
nFldcq7gct6PYxDOI2usLZOCJznYrAdvK0y0ffAPdSefiwBhl6CCwvsmkdJlBRl0E9sQB+9mW4M+
yDaXusVHgJtazqJoLg2WHBYKbCgtKKtOd6NgG6fP9+P0uzrr8mvn0mvUfVY7pUbDfrsE4an3/+G/
9kEr+JjHswW87oQrINe/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAE/ptuvHAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" path="m,l9144,r,282245l,282245,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,282245"/>
 </v:shape><v:rect id="Rectangle_x0020_1015" o:spid="_x0000_s1040" style='position:absolute;
  left:4800;top:3762;width:10748;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>dTT [ng/mL]<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1016" o:spid="_x0000_s1041" style='position:absolute;
  left:12877;top:3762;width:507;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_39565" o:spid="_x0000_s1042" style='position:absolute;
  left:33686;top:3762;width:2027;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>67<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_39566" o:spid="_x0000_s1043" style='position:absolute;
  left:33305;top:3762;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_39564" o:spid="_x0000_s1044" style='position:absolute;
  left:32451;top:3762;width:1143;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCXkSr7xwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvhX6H5RW81U2tiomuIrZFj/4D9fbIPpPQ7NuQXU3007tCocdhZn7DTGatKcWValdYVvDRjUAQ
p1YXnCnY737eRyCcR9ZYWiYFN3Iwm76+TDDRtuENXbc+EwHCLkEFufdVIqVLczLourYiDt7Z1gZ9
kHUmdY1NgJtS9qJoKA0WHBZyrGiRU/q7vRgFy1E1P67svcnK79PysD7EX7vYK9V5a+djEJ5a/x/+
a6+0gs94MOzD8064AnL6AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJeRKvvHAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>&gt;<o:p>&nbsp;</o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1018" o:spid="_x0000_s1045" style='position:absolute;
  left:35210;top:3762;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:shape id="Shape_x0020_46830" o:spid="_x0000_s1046" style='position:absolute;
  left:4556;top:3112;width:91;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46831" o:spid="_x0000_s1047" style='position:absolute;
  left:4647;top:3112;width:27560;height:92;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2756027,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l2756027,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2756027,9144"/>
 </v:shape><v:shape id="Shape_x0020_46832" o:spid="_x0000_s1048" style='position:absolute;
  left:32207;top:3112;width:92;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46833" o:spid="_x0000_s1049" style='position:absolute;
  left:32299;top:3112;width:22862;height:92;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2286254,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2286254,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2286254,9144"/>
 </v:shape><v:shape id="Shape_x0020_46834" o:spid="_x0000_s1050" style='position:absolute;
  left:55163;top:3112;width:91;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46835" o:spid="_x0000_s1051" style='position:absolute;
  left:4556;top:3402;width:91;height:2819;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46836" o:spid="_x0000_s1052" style='position:absolute;
  left:32207;top:3402;width:92;height:2819;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46837" o:spid="_x0000_s1053" style='position:absolute;
  left:55163;top:3402;width:91;height:2819;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:rect id="Rectangle_x0020_1027" o:spid="_x0000_s1054" style='position:absolute;
  left:4800;top:6871;width:6024;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>ECT [x<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1028" o:spid="_x0000_s1055" style='position:absolute;
  left:9326;top:6871;width:675;height:1844;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>-<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1029" o:spid="_x0000_s1056" style='position:absolute;
  left:9829;top:6871;width:21828;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>fold upper limit of normal]<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1030" o:spid="_x0000_s1057" style='position:absolute;
  left:26261;top:6871;width:507;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBnx2A0xwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
EIXvBf/DMkJvdaOFojEbEW3RY9WC9TZkp0lodjZktybtr+8cBG8zvDfvfZOtBteoK3Wh9mxgOklA
ERfe1lwa+Di9Pc1BhYhssfFMBn4pwCofPWSYWt/zga7HWCoJ4ZCigSrGNtU6FBU5DBPfEov25TuH
Udau1LbDXsJdo2dJ8qId1iwNFba0qaj4Pv44A7t5u/7c+7++bF4vu/P7ebE9LaIxj+NhvQQVaYh3
8+16bwU/eRZ++UZG0Pk/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGfHYDTHAAAA3QAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1031" o:spid="_x0000_s1058" style='position:absolute;
  left:32451;top:6871;width:6349;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAIi8WvwgAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Li8Iw
EL4L/ocwgjdNVRDtGkV8oEdXBXdvQzPbFptJaaKt/nqzIHibj+85s0VjCnGnyuWWFQz6EQjixOqc
UwXn07Y3AeE8ssbCMil4kIPFvN2aYaxtzd90P/pUhBB2MSrIvC9jKV2SkUHXtyVx4P5sZdAHWKVS
V1iHcFPIYRSNpcGcQ0OGJa0ySq7Hm1Gwm5TLn7191mmx+d1dDpfp+jT1SnU7zfILhKfGf8Rv916H
+dFoAP/fhBPk/AUAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAIi8WvwgAAAN0AAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>No data<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1032" o:spid="_x0000_s1059" style='position:absolute;
  left:37237;top:6871;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:shape id="Shape_x0020_46838" o:spid="_x0000_s1060" style='position:absolute;
  left:4556;top:6221;width:91;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46839" o:spid="_x0000_s1061" style='position:absolute;
  left:4647;top:6221;width:27560;height:92;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2756027,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l2756027,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2756027,9144"/>
 </v:shape><v:shape id="Shape_x0020_46840" o:spid="_x0000_s1062" style='position:absolute;
  left:32207;top:6221;width:92;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46841" o:spid="_x0000_s1063" style='position:absolute;
  left:32299;top:6221;width:22862;height:92;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2286254,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2286254,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2286254,9144"/>
 </v:shape><v:shape id="Shape_x0020_46842" o:spid="_x0000_s1064" style='position:absolute;
  left:55163;top:6221;width:91;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46843" o:spid="_x0000_s1065" style='position:absolute;
  left:4556;top:6511;width:91;height:2819;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46844" o:spid="_x0000_s1066" style='position:absolute;
  left:32207;top:6511;width:92;height:2819;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD87TMaxwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9bawIx
FITfC/6HcARfimZr1yCrUWyxUCgIXvD5sDl7wc3JdhN1/fdNodDHYWa+YZbr3jbiRp2vHWt4mSQg
iHNnai41nI4f4zkIH5ANNo5Jw4M8rFeDpyVmxt15T7dDKEWEsM9QQxVCm0np84os+olriaNXuM5i
iLIrpenwHuG2kdMkUdJizXGhwpbeK8ovh6vV8Jao1+L7efv1kGp7Vjtsi/Q603o07DcLEIH68B/+
a38aDamapyn83olXQK5+AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPztMxrHAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46845" o:spid="_x0000_s1067" style='position:absolute;
  left:55163;top:6511;width:91;height:2819;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:rect id="Rectangle_x0020_1041" o:spid="_x0000_s1068" style='position:absolute;
  left:4800;top:9965;width:6686;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>aPTT [x<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1042" o:spid="_x0000_s1069" style='position:absolute;
  left:9829;top:9965;width:675;height:1844;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>-<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1043" o:spid="_x0000_s1070" style='position:absolute;
  left:10332;top:9965;width:14938;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>fold upper limit of<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1044" o:spid="_x0000_s1071" style='position:absolute;
  left:21567;top:9965;width:507;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1045" o:spid="_x0000_s1072" style='position:absolute;
  left:21948;top:9965;width:6408;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>normal]<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1046" o:spid="_x0000_s1073" style='position:absolute;
  left:26779;top:9965;width:507;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1047" o:spid="_x0000_s1074" style='position:absolute;
  left:32451;top:9965;width:4176;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>&gt; 1.3<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1048" o:spid="_x0000_s1075" style='position:absolute;
  left:35591;top:9965;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:shape id="Shape_x0020_46846" o:spid="_x0000_s1076" style='position:absolute;
  left:4556;top:9330;width:91;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46847" o:spid="_x0000_s1077" style='position:absolute;
  left:4647;top:9330;width:27560;height:92;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2756027,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l2756027,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2756027,9144"/>
 </v:shape><v:shape id="Shape_x0020_46848" o:spid="_x0000_s1078" style='position:absolute;
  left:32207;top:9330;width:92;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46849" o:spid="_x0000_s1079" style='position:absolute;
  left:32299;top:9330;width:22862;height:92;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2286254,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2286254,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2286254,9144"/>
 </v:shape><v:shape id="Shape_x0020_46850" o:spid="_x0000_s1080" style='position:absolute;
  left:55163;top:9330;width:91;height:290;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46851" o:spid="_x0000_s1081" style='position:absolute;
  left:4556;top:9620;width:91;height:2804;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,280416" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,280416l,280416,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,280416"/>
 </v:shape><v:shape id="Shape_x0020_46852" o:spid="_x0000_s1082" style='position:absolute;
  left:32207;top:9620;width:92;height:2804;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,280416" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,280416l,280416,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,280416"/>
 </v:shape><v:shape id="Shape_x0020_46853" o:spid="_x0000_s1083" style='position:absolute;
  left:55163;top:9620;width:91;height:2804;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,280416" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,280416l,280416,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,280416"/>
 </v:shape><v:rect id="Rectangle_x0020_1057" o:spid="_x0000_s1084" style='position:absolute;
  left:4800;top:13074;width:3480;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>INR<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1058" o:spid="_x0000_s1085" style='position:absolute;
  left:7421;top:13074;width:507;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1059" o:spid="_x0000_s1086" style='position:absolute;
  left:32451;top:13074;width:20184;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>Should not be performed<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1060" o:spid="_x0000_s1087" style='position:absolute;
  left:47649;top:13074;width:507;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB0dE8pxQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bb8Iw
DIXvk/gPkZG4jZQdEBQCQrAJjhsgATerMW1F41RNRst+/XxA4mbrPb/3eb7sXKXu1ITSs4HRMAFF
nHlbcm7gePh6n4AKEdli5ZkMPCjActF7m2Nqfcs/dN/HXEkIhxQNFDHWqdYhK8hhGPqaWLSrbxxG
WZtc2wZbCXeV/kiSsXZYsjQUWNO6oOy2/3UGtpN6dd75vzavPi/b0/dpujlMozGDfreagYrUxZf5
eb2zgp+MhV++kRH04h8AAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB0dE8pxQAAAN0AAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:shape id="Shape_x0020_46854" o:spid="_x0000_s1088" style='position:absolute;
  left:4556;top:12424;width:91;height:289;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46855" o:spid="_x0000_s1089" style='position:absolute;
  left:4647;top:12424;width:27560;height:91;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2756027,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l2756027,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2756027,9144"/>
 </v:shape><v:shape id="Shape_x0020_46856" o:spid="_x0000_s1090" style='position:absolute;
  left:32207;top:12424;width:92;height:289;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46857" o:spid="_x0000_s1091" style='position:absolute;
  left:32299;top:12424;width:22862;height:91;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2286254,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2286254,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2286254,9144"/>
 </v:shape><v:shape id="Shape_x0020_46858" o:spid="_x0000_s1092" style='position:absolute;
  left:55163;top:12424;width:91;height:289;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,28956" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,28956l,28956,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,28956"/>
 </v:shape><v:shape id="Shape_x0020_46859" o:spid="_x0000_s1093" style='position:absolute;
  left:4556;top:12713;width:91;height:2820;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46860" o:spid="_x0000_s1094" style='position:absolute;
  left:4556;top:15533;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_46861" o:spid="_x0000_s1095" style='position:absolute;
  left:4647;top:15533;width:27560;height:91;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2756027,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l2756027,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2756027,9144"/>
 </v:shape><v:shape id="Shape_x0020_46862" o:spid="_x0000_s1096" style='position:absolute;
  left:32207;top:12713;width:92;height:2820;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46863" o:spid="_x0000_s1097" style='position:absolute;
  left:32207;top:15533;width:92;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_46864" o:spid="_x0000_s1098" style='position:absolute;
  left:32299;top:15533;width:22862;height:91;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="2286254,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBXUG1ZyQAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvhf6H5RV6KXWjaJDoKmoJ1YNQbUWPr9nXJJp9G7Krxn/fFQo9DjPzDTOetqYSF2pcaVlBtxOB
IM6sLjlX8PWZvg5BOI+ssbJMCm7kYDp5fBhjou2VN3TZ+lwECLsEFRTe14mULivIoOvYmjh4P7Yx
6INscqkbvAa4qWQvimJpsOSwUGBNi4Ky0/ZsFBBvdh/p+nvw8jbvHfYlHlfp+1Gp56d2NgLhqfX/
4b/2Uivox8O4D/c74QrIyS8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAA
AAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAV
AQAACwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAV1BtWckAAADe
AAAADwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAP0CAAAA
AA==
" path="m,l2286254,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2286254,9144"/>
 </v:shape><v:shape id="Shape_x0020_46865" o:spid="_x0000_s1099" style='position:absolute;
  left:55163;top:12713;width:91;height:2820;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="9144,281940" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,281940l,281940,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,281940"/>
 </v:shape><v:shape id="Shape_x0020_46866" o:spid="_x0000_s1100" style='position:absolute;
  left:55163;top:15533;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_46867" o:spid="_x0000_s1101" style='position:absolute;
  top:15624;width:59810;height:2637;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5981065,263652" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l5981065,r,263652l,263652,,e" stroked="f" strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5981065,263652"/>
 </v:shape><v:rect id="Rectangle_x0020_1077" o:spid="_x0000_s1102" style='position:absolute;
  left:182;top:15985;width:49453;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>Patients who develop acute renal failure must
     discontinue <o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1078" o:spid="_x0000_s1103" style='position:absolute;
  left:37633;top:15985;width:25142;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>Dabigatran Etexilate Capsules<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_1079" o:spid="_x0000_s1104" style='position:absolute;
  left:56550;top:15985;width:506;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'><span style='mso-spacerun:yes'> </span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_39569" o:spid="_x0000_s1105" style='position:absolute;
  left:57174;top:15985;width:675;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>(<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_39570" o:spid="_x0000_s1106" style='position:absolute;
  left:57682;top:15985;width:3093;height:1844;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBtc7olxwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NasJA
FIX3Bd9huEJ3daKlrUkzitgWXWosRHeXzG0SzNwJmalJfXpnUXB5OH986XIwjbhQ52rLCqaTCARx
YXXNpYLvw9fTHITzyBoby6TgjxwsF6OHFBNte97TJfOlCCPsElRQed8mUrqiIoNuYlvi4P3YzqAP
siul7rAP46aRsyh6lQZrDg8VtrSuqDhnv0bBZt6ujlt77cvm87TJd3n8cYi9Uo/jYfUOwtPg7+H/
9lYreI5f3gJAwAkoIBc3AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAG1zuiXHAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
     margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
     line-height:107%'>see <o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="662" height="192" alt="" vspace="0" hspace="0" border="0" style="width:662px;height:192px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:472.5pt;height:143.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>section 4.3).</p><p>Limited data is available in patients &lt; 50 kg (see section 5.2).&nbsp;</p><p>When severe bleedings occur treatment must be discontinued and the source of bleeding investigated (see section 4.9).</p><p>Medicinal products that may enhance the risk of haemorrhage should not be administered concomitantly or should be administered with caution with Dabigatran Etexilate Capsules (see section 4.5).</p><p>Use of fibrinolytic medicinal products for the treatment of acute ischemic stroke&nbsp;</p><p>The use of fibrinolytic medicinal products for the treatment of acute ischemic stroke may be considered if the patient presents with a dTT, ECT or aPTT not exceeding the ULN according to the local reference range.</p><p>Interaction with P-gp inducers&nbsp;</p><p>Concomitant administration of P-gp inducers (such as rifampicin, St. John`s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran plasma concentrations, and should be avoided (see sections 4.5 and 5.2).</p><p>Surgery and interventions&nbsp;</p><p>Patients on dabigatran etexilate who undergo surgery or invasive procedures are at increased risk for bleeding. Therefore surgical interventions may require the temporary discontinuation of dabigatran etexilate.</p><p>Caution should be exercised when treatment is temporarily discontinued for interventions and anticoagulant monitoring is warranted. Clearance of dabigatran in patients with renal insufficiency may take longer (see section 5.2). This should be considered in advance of any procedures. In such cases a coagulation test (see sections 4.4 and 5.1) may help to determine whether haemostasis is still impaired.</p><p>Emergency surgery or urgent procedures&nbsp;</p><p>Dabigatran etexilate should be temporarily discontinued. When rapid reversal of the anticoagulation effect is required the specific reversal agent (Praxbind, idarucizumab) to Dabigatran Etexilate Capsules is available.&nbsp;</p><p>Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease. Dabigatran Etexilate Capsules treatment can be re-initiated 24 hours after administration of Praxbind (idarucizumab), if the patient is clinically stable and adequate haemostasis has been achieved.&nbsp;</p><p>Subacute surgery/interventions&nbsp;</p><p>Dabigatran etexilate should be temporarily discontinued. A surgery / intervention should be delayed if possible until at least 12 hours after the last dose. If surgery cannot be delayed the risk of bleeding may be increased. This risk of bleeding should be weighed against the urgency of intervention.</p><p>Elective surgery&nbsp;</p><p>If possible, Dabigatran Etexilate Capsules should be discontinued at least 24 hours before invasive or surgical procedures. In patients at higher risk of bleeding or in major surgery where complete haemostasis may be required consider stopping Dabigatran Etexilate Capsules 2-4 days before surgery. Clearance of dabigatran in patients with renal insufficiency may take longer. This should be considered in advance of any procedures.&nbsp;</p><p>Table 3 summarises discontinuation rules before invasive or surgical procedures.</p><p>Table 3: Discontinuation rules before invasive or surgical procedures</p><table border="0" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>Renal function</p><p>(CrCL &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</p><p>mL/min)</p><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_45203" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:88.5pt;
   height:15pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
    o:title=""/>
  </v:shape><![endif]--><img width="118" height="20" alt="" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></p><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_45204" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:88.5pt;
   height:15pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
    o:title=""/>
  </v:shape><![endif]--><img width="118" height="20" alt="" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></p><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_45205" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:88.5pt;
   height:15pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
    o:title=""/>
  </v:shape><![endif]--><img width="118" height="20" alt="" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /></p></td><td rowspan="2" style="vertical-align:top"><p>Estimated half-life&nbsp;</p><p>(hours)</p></td><td colspan="2" style="vertical-align:top"><p>Stop dabigatran before elective surgery</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>High risk of bleeding or major surgery</p></td><td style="vertical-align:top"><p>Standard risk</p></td></tr><tr><td style="vertical-align:top"><p>~ 13</p></td><td style="vertical-align:top"><p>2 days before</p></td><td style="vertical-align:top"><p>24 hours before</p></td></tr><tr><td style="vertical-align:top"><p>~ 15</p></td><td style="vertical-align:top"><p>2-3 days before</p></td><td style="vertical-align:top"><p>1-2 days before</p></td></tr><tr><td style="vertical-align:top"><p>~ 18</p></td><td style="vertical-align:top"><p>4 days before</p></td><td style="vertical-align:top"><p>2-3 days before</p><p>(&gt; 48 hours)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><u>Spinal anaesthesia/epidural anaesthesia/lumbar puncture</u>&nbsp;</p></td></tr></tbody></table><p>Procedures such as spinal anaesthesia may require complete haemostatic function.</p><p>The risk of spinal or epidural haematoma may be increased in cases of traumatic or repeated puncture and by the prolonged use of epidural catheters. After removal of a catheter, an interval of at least 2 hours should elapse before the administration of the first dose of dabigatran etexilate. These patients require frequent observation for neurological signs and symptoms of spinal or epidural haematoma.</p><p>Postoperative phase&nbsp;</p><p>Dabigatran etexilate should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established.&nbsp;</p><p>Patients at risk for bleeding or patients at risk of overexposure, notably patients with moderate renal impairment (CrCL 30-50 mL/min), should be treated with caution (see sections 4.4 and</p><p>5.1).&nbsp;</p><p><u>Patients at high surgical mortality risk and with intrinsic risk factors for thromboembolic events</u>&nbsp; There are limited efficacy and safety data for dabigatran available in these patients and therefore they should be treated with caution.</p><p>Hip fracture surgery&nbsp;</p><p>There is no data on the use of Dabigatran Etexilate Capsules in patients undergoing hip fracture surgery. Therefore treatment is not recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anticoagulants and antiplatelet aggregation medicinal products&nbsp;</p><p>There is no or only limited experience with the following treatments which may increase the risk of bleeding when used concomitantly with Dabigatran Etexilate Capsules: anticoagulants such as unfractionated heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux, desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral anticoagulants (see section 4.3), and platelet aggregation medicinal products such as, GPIIb/IIIa receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).</p><p>UFH can be administered at doses necessary to maintain a patent central venous or arterial catheter (see sections 4.3).</p><p>Clopidogrel: In a phase I study in young healthy male volunteers, the concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy. In addition, dabigatran AUC<!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1571" o:spid="_x0000_i1030" type="#_x0000_t75"
 style='width:6pt;height:7.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" />,ss and C<sub>max</sub>,ss and the coagulation measures for dabigatran effect or the inhibition of platelet aggregation as measure of clopidogrel effect remained essentially unchanged comparing combined treatment and the respective mono-treatments. With a loading dose of 300 mg or 600 mg clopidogrel, dabigatran AUC<!--[if gte vml 1]><v:shape id="Picture_x0020_1587" o:spid="_x0000_i1029"
 type="#_x0000_t75" style='width:6pt;height:7.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" />,ss and C<sub>max</sub>,ss were increased by about 30-40 % (see section 4.4).</p><p>ASA: The effect of concomitant administration of dabigatran etexilate and ASA on the risk of bleeds was studied in patients with atrial fibrillation in a phase II study in which a randomized ASA co-administration was applied. Based on logistic regression analysis, co-administration of</p><p>ASA and 150 mg dabigatran etexilate twice daily may increase the risk for any bleeding from 12 % to 18 % and 24 % with 81 mg and 325 mg ASA, respectively (see section 4.4).</p><p>NSAIDs: NSAIDs given for short-term perioperative analgesia have been shown not to be associated with increased bleeding risk when given in conjunction with dabigatran etexilate. With chronic use NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin. Therefore, due to the risk of haemorrhage, notably with NSAIDs with elimination half-lives &gt; 12 hours, close observation for signs of bleeding is recommended (see section 4.4).</p><p>LMWH: The concomitant use of LMWHs, such as enoxaparin and dabigatran etexilate has not been specifically investigated. After switching from 3-day treatment of once daily 40 mg enoxaparin s.c., 24 hours after the last dose of enoxaparin the exposure to dabigatran was slightly lower than that after administration of dabigatran etexilate (single dose of 220 mg) alone. A higher anti-FXa/FIIa activity was observed after dabigatran etexilate administration with enoxaparin pre-treatment compared to that after treatment with dabigatran etexilate alone. This is considered to be due to the carry-over effect of enoxaparin treatment, and regarded as not clinically relevant. Other dabigatran related anti-coagulation tests were not changed significantly by the pre-treatment of enoxaparin.</p><p>Interactions linked to dabigatran etexilate and dabigatran metabolic profile&nbsp;</p><p>Dabigatran etexilate and dabigatran are not metabolised by the cytochrome P450 system and have no in vitro effects on human cytochrome P450 enzymes. Therefore, related medicinal product interactions are not expected with dabigatran.</p><p>Transporter interactions&nbsp; P-gp inhibitors&nbsp;</p><p>Dabigatran etexilate is a substrate for the efflux transporter P-gp. Concomitant administration of P-gp inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, clarithromycin and ticagrelor) is expected to result in increased dabigatran plasma concentrations.&nbsp;</p><p>If not otherwise specifically described, close clinical surveillance (looking for signs of bleeding or anaemia) is required when dabigatran is co-administered with strong P-gp inhibitors. A coagulation test helps to identify patients with an increased bleeding risk due to increased dabigatran exposure (see sections 4.2, 4.4 and 5.1).</p><p>The following strong P-gp inhibitors are contraindicated: systemic ketoconazole, cyclosporine, itraconazole and dronedarone (see section 4.3). Concomitant treatment with tacrolimus is not recommended. Caution should be exercised with mild to moderate P-gp inhibitors (e.g. amiodarone, posaconazole, quinidine, verapamil and ticagrelor) (see sections 4.2 and 4.4).</p><p>Ketoconazole: Ketoconazole increased total dabigatran AUC<sub>0-&infin;</sub> and C<sub>max</sub> values by 138 % and 135 %, respectively, after a single oral dose of 400 mg, and 153 % and 149 %, respectively, after multiple oral dosing of 400 mg ketoconazole once daily. The time to peak, terminal half-life and mean residence time were not affected by ketoconazole (see section 4.4). Concomitant treatment with systemic ketoconazole is contraindicated (see section 4.3).</p><p>Dronedarone: When dabigatran etexilate and dronedarone were given at the same time total dabigatran AUC<sub>0-&infin;</sub> and C<sub>max</sub> values increased by about 2.4-fold and 2.3-fold (+136 % and 125 %), respectively, after multiple dosing of 400 mg dronedarone bid, and about 2.1-fold and 1.9fold (+114 % and 87 %), respectively, after a single dose of 400 mg. The terminal half-life and renal clearance of dabigatran were not affected by dronedarone. When single and multiple doses of dronedarone were given 2 h after dabigatran etexilate, the increases in dabigatran AUC<sub>0-&infin;</sub> were 1.3-fold and 1.6-fold, respectively. Concomitant treatment with dronedarone is contraindicated.</p><p>Amiodarone: When Dabigatran Etexilate Capsules was co-administered with a single oral dose of 600 mg amiodarone, the extent and rate of absorption of amiodarone and its active metabolite DEA were essentially unchanged. The dabigatran AUC and C<sub>max</sub> were increased by about 60 % and 50 %, respectively. The mechanism of the interaction has not been completely clarified. In view of the long half-life of amiodarone the potential for drug interaction may exist for weeks after discontinuation of amiodarone (see sections 4.2 and 4.4).&nbsp;</p><p>Patients treated for prevention of VTEs after hip or knee replacement surgery, dosing should be reduced to 150 mg taken once daily as 2 capsules of 75 mg Dabigatran Etexilate Capsules if they receive concomitantly dabigatran etexilate and amiodarone (see section 4.2). Close clinical surveillance is recommended when dabigatran etexilate is combined with amiodarone and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.</p><p>Quinidine: Quinidine was given as 200 mg dose every 2nd hour up to a total dose of 1,000 mg. Dabigatran etexilate was given twice daily over 3 consecutive days, on the 3<sup>rd</sup> day either with or without quinidine. Dabigatran AUC<!--[if gte vml 1]><v:shape
 id="Picture_x0020_1905" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:6pt;
 height:7.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" />,ss and C<sub>max</sub>,ss were increased on average by 53 % and 56 %, respectively with concomitant quinidine (see sections 4.2 and 4.4).&nbsp;</p><p>Patients treated for prevention of VTEs after hip or knee replacement surgery, dosing should be reduced to 150 mg taken once daily as 2 capsules of 75 mg Dabigatran Etexilate Capsules if they receive concomitantly dabigatran etexilate and quinidine (see section 4.2). Close clinical surveillance is recommended when dabigatran etexilate is combined with quinidine and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.</p><p>Verapamil: When dabigatran etexilate (150 mg) was co-administered with oral verapamil, the C<sub>max</sub> and AUC of dabigatran were increased but magnitude of this change differs depending on timing of administration and formulation of verapamil (see sections 4.2 and 4.4).</p><p>The greatest elevation of dabigatran exposure was observed with the first dose of an immediate release formulation of verapamil administered one hour prior to dabigatran etexilate intake (increase of C<sub>max</sub> by about 180 % and AUC by about 150 %). The effect was progressively decreased with administration of an extended release formulation (increased of C<sub>max</sub> by about 90 % and AUC by about 70 %) or administration of multiple doses of verapamil (increased of C<sub>max</sub> by about 60 % and AUC by about 50 %).</p><p>Therefore, close clinical surveillance (looking for signs of bleeding or anaemia) is required when dabigatran is co-administered with verapamil. In patients with normal renal function after the hip or knee replacement surgery, receiving dabigatran etexilate and verapamil concomitantly, the dose of Dabigatran Etexilate Capsules should be reduced to 150 mg taken once daily as 2 capsules of 75 mg . In patients with moderate renal impairment and concomitantly treated with dabigatran etexilate and verapamil, a dose reduction of Dabigatran Etexilate Capsules to 75 mg daily should be considered (see sections 4.2 and 4.4). Close clinical surveillance is recommended when dabigatran etexilate is combined with verapamil and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.</p><p>There was no meaningful interaction observed when verapamil was given 2 hours after dabigatran etexilate (increased of C<sub>max</sub> by about 10 % and AUC by about 20 %). This is explained by completed dabigatran absorption after 2 hours (see section 4.4).</p><p>Clarithromycin: When clarithromycin (500 mg twice daily) was administered together with dabigatran etexilate in healthy volunteers, increase of AUC by about 19 % and C<sub>max</sub> by about 15</p><p>% was observed without any clinical safety concern. However, in patients receiving dabigatran, a clinically relevant interaction cannot be excluded when combined with clarithromycin. Therefore, a close monitoring should be exercised when dabigatran etexilate is combined with clarithromycin and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.</p><p>Ticagrelor: When a single dose of 75mg dabigatran etexilate was coadministered simultaneously with a loading dose of 180 mg ticagrelor, the dabigatran AUC and C<sub>max</sub>were increased by 1.73fold and 1.95-fold (+73% and 95 %), respectively. After multiple doses of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is 1.56-fold and 1.46-fold (+56% and 46%) for C<sub>max</sub> and AUC, respectively.</p><p>Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg dabigatran etexilate (in steady state) increased the dabigatran AUC<!--[if gte vml 1]><v:shape
 id="Picture_x0020_2096" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:6pt;
 height:7.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" />,ss and Cmax,ss by 1.49-fold and 1.65fold (+49% and 65%), respectively, compared with dabigatran etexilate given alone. When a loading dose of 180 mg ticagrelor was given 2 hours after 110 mg dabigatran etexilate (in steady state), the increase of dabigatran AUC<!--[if gte vml 1]><v:shape id="Picture_x0020_2112"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:6pt;height:7.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" />,ss and Cmax,ss was reduced to 1.27-fold and 1.23-fold (+27% and 23%), respectively, compared with dabigatran etexilate given alone. This staggered intake is the recommended administration for start of ticagrelor with a loading dose.</p><p>Concomitant administration of 90 mg ticagrelor BID (maintenance dose) with 110 mg dabigatran etexilate increased the adjusted dabigatran AUC<!--[if gte vml 1]><v:shape
 id="Picture_x0020_2129" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:6pt;
 height:7.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg" />,ss and Cmax,ss 1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given alone.</p><p>The following potent P-gp inhibitors have not been clinically studied but from in vitro results a similar effect as with ketoconazole may be expected:&nbsp;</p><p>Itraconazole and cyclosporine, which are contra-indicated (see section 4.3).</p><p>Tacrolimus has been found in vitro to have a similar level of inhibitory effect on P-gp as that seen with itraconazole and cyclosporine. Dabigatran etexilate has not been clinically studied together with tacrolimus. However, limited clinical data with another P-gp substrate (everolimus) suggest that the inhibition of P-gp with tacrolimus is weaker than that observed with strong P-gp inhibitors. Based on these data concomitant treatment with tacrolimus is not recommended.&nbsp; Posaconazole also inhibits P-gp to some extent but has not been clinically studied. Caution should be exercised when Dabigatran Etexilate Capsules is co-administered with posaconazole.</p><p>P-gp inducers&nbsp;</p><p>Concomitant administration of a P-gp inducer (such as rifampicin, St. John&acute;s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran concentrations and should be avoided (see sections 4.4 and 5.2).</p><p>Rifampicin: Pre-dosing of the probe inducer rifampicin at a dose of 600 mg once daily for 7 days decreased total dabigatran peak and total exposure by 65.5 and 67 %, respectively. The inducing effect was diminished resulting in dabigatran exposure close to the reference by day 7 after cessation of rifampicin treatment. No further increase in bioavailability was observed after another 7 days.</p><p>Other medicinal products affecting P-gp&nbsp;</p><p>Protease inhibitors including ritonavir and its combinations with other protease inhibitors affect P-gp (either as inhibitor or as inducer). They have not been studied and are therefore not recommended for concomitant treatment with Dabigatran Etexilate Capsules.</p><p>P-gp substrate&nbsp;</p><p>Digoxin: In a study performed with 24 healthy subjects, when Dabigatran Etexilate Capsules was co-administered with digoxin, no changes on digoxin and no clinical relevant changes on dabigatran exposure have been observed.</p><p><u>Co-medication with selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin</u> <u>norepinephrine re-uptake inhibitors (SNRIs)</u>&nbsp;</p><p>SSRIs and SNRIs increased the risk of bleeding in RE-LY in all treatment groups.</p><p>Gastric pH&nbsp;</p><p>Pantoprazole: When Dabigatran Etexilate Capsules was co-administered with pantoprazole, a decrease in the dabigatran area under the plasma concentration-time curve of approximately 30 % was observed. Pantoprazole and other proton-pump inhibitors (PPI) were co-administered with Dabigatran Etexilate Capsules in clinical trials, and concomitant PPI treatment did not appear to reduce the efficacy of Dabigatran Etexilate Capsules.</p><p>Ranitidine: Ranitidine administration together with Dabigatran Etexilate Capsules had no clinically relevant effect on the extent of absorption of dabigatran.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females&nbsp;</u></p><p>Women of childbearing potential should avoid pregnancy during treatment with dabigatran etexilate.</p><p><u>Pregnancy&nbsp;</u></p><p>There are limited amount of data from the use of dabigatran etexilate in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>Dabigatran Etexilate Capsules should not be used during pregnancy unless clearly necessary.</p><p><u>Breast-feeding&nbsp;</u></p><p>There are no clinical data of the effect of dabigatran on infants during breast-feeding.</p><p>Breast-feeding should be discontinued during treatment with Dabigatran Etexilate Capsules. <u>Fertility</u>&nbsp;</p><p>No human data available.</p><p>In animal studies an effect on female fertility was observed in the form of a decrease in implantations and an increase in pre-implantation loss at 70 mg/kg (representing a 5-fold higher plasma exposure level compared to patients). No other effects on female fertility were observed. There was no influence on male fertility. At doses that were toxic to the mothers (representing a 5- to 10-fold higher plasma exposure level to patients), a decrease in foetal body weight and embryofoetal viability along with an increase in foetal variations were observed in rats and rabbits. In the pre- and post-natal study, an increase in foetal mortality was observed at doses that were toxic to the dams (a dose corresponding to a plasma exposure level 4-fold higher than observed in patients).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dabigatran Etexilate Capsules has no or negligible influence on the ability to drive and use machines.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>A total of 10,795 patients were treated in 6 actively controlled VTE prevention trials with at least one dose of the medicinal product. Of these 6,684 were treated with 150 mg or 220 mg daily of Dabigatran Etexilate Capsules.</p><p>The most commonly reported adverse reactions are bleedings occurring in total in approximately</p><p>14 % of patients; the frequency of major bleeds (including wound site bleedings) is less than 2 %.</p><p>Although rare in frequency in clinical trials, major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.</p><p>Tabulated list of adverse reactions&nbsp;</p><p>Table 4 shows the adverse reactions ranked under headings of System Organ Classes (SOC) and frequency using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>Table 4: Adverse reactions</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:560px"><tbody><tr><td style="vertical-align:top"><p>SOC / Preferred term.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Haematocrit decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug hypersensitivity&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intracranial haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haematoma</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Wound haemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Haemorrhage</p></td><td style="vertical-align:top"><p>Rare&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:560px"><tbody><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Epistaxis&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Haemoptysis</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Gastrointestinal haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rectal haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Haemorrhoidal haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Diarrhoea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Nausea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Vomiting</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Gastrointestinal ulcer, including oesophageal ulcer&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Gastroesophagitis&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Gastroesophageal reflux disease&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Abdominal pain</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Dyspepsia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Dysphagia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic function abnormal/ Liver function Test abnormal</p></td><td colspan="2" style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Hyperbilirubinaemia</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorder</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Skin haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="18" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Haemarthrosis</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" rowspan="18" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Genitourological haemorrhage, including haematuria</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Injection site haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Catheter site haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bloody discharge</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Traumatic haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Post procedural haematoma</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Post procedural haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Post procedural discharge</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Wound secretion</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Incision site haemorrhage</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Anaemia postoperative</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Surgical and medical procedures</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Wound drainage</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Post procedural drainage</p></td><td colspan="2" style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Bleeding</u>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>The table 5 shows the number (%) of patients experiencing the adverse reaction bleeding during the treatment period in the VTE prevention in the two pivotal clinical trials, according to dose.</p><p>Table 5: Number (%) of patients experiencing the adverse reaction bleeding</p><table border="0" cellspacing="0" cellpadding="0" style="width:560px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dabigatran etexilate</p><p>150 mg</p><p>N (%)</p></td><td style="vertical-align:top"><p>Dabigatran etexilate</p><p>220 mg</p><p>N (%)</p></td><td style="vertical-align:top"><p>Enoxaparin</p><p>N (%)</p></td></tr><tr><td style="vertical-align:top"><p>Treated</p></td><td style="vertical-align:top"><p>1,866 (100.0)</p></td><td style="vertical-align:top"><p>1,825 (100.0)</p></td><td style="vertical-align:top"><p>1,848 (100.0)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding</p></td><td style="vertical-align:top"><p>24 (1.3)</p></td><td style="vertical-align:top"><p>33 (1.8)</p></td><td style="vertical-align:top"><p>27 (1.5)</p></td></tr><tr><td style="vertical-align:top"><p>Any bleeding</p></td><td style="vertical-align:top"><p>258 (13.8)</p></td><td style="vertical-align:top"><p>251 (13.8)</p></td><td style="vertical-align:top"><p>247 (13.4)</p></td></tr></tbody></table><p>The definition of the adverse reaction major bleeding in the RE-NOVATE and RE-MODEL studies were as follows:</p><p>&bull;&nbsp; fatal bleeding</p><p>&bull;&nbsp; clinically overt bleeding in excess of what was expected and associated with &ge; 20 g/L (corresponds to 1.24 mmol/L) fall in haemoglobin in excess of what was expected</p><p>&bull;&nbsp; clinically overt bleeding in excess of what was expected and leading to transfusion of &ge; 2 units packed cells or whole blood in excess of what was expected</p><p>&bull;&nbsp; symptomatic retroperitoneal, intracranial, intraocular or intraspinal bleeding</p><p>&bull;&nbsp; bleeding requiring treatment cessation</p><p>&bull;&nbsp; bleeding leading to re-operation</p><p>Objective testing was required for a retroperitoneal bleed (ultrasound or Computer Tomography (CT) scan) and for an intracranial and intraspinal bleed (CT scan or Magnetic Resonance Imaging).</p><p><u><strong>Reporting of suspected adverse reactions</strong></u>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: <u>npc.drug@sfda.gov.sa</u><br />o Website: <u>www.sfda.gov.sa/npc</u></p></td></tr></tbody></table><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses of dabigatran etexilate beyond those recommended, expose the patient to increased risk of bleeding.</p><p>In case of an overdose suspicion, coagulation tests can help to determine a bleeding risk (see sections 4.4 and 5.1). A calibrated quantitative dTT test or repetitive dTT measurements allow prediction of the time by when certain dabigatran levels will be reached (see section 5.1), also in case additional measures e.g. dialysis have been initiated.</p><p>Excessive anticoagulation may require interruption of Dabigatran Etexilate Capsules treatment. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. Since dabigatran is excreted predominantly by the renal route adequate diuresis must be maintained. Depending on the clinical situation appropriate supportive treatment, such as surgical haemostasis and blood volume replacement, should be undertaken at the prescribers discretion.&nbsp;</p><p>For situations when rapid reversal of the anticoagulant effect of Dabigatran Etexilate Capsules is required the specific reversal agent (Praxbind, idarucizumab) antagonizing the pharmacodynamics effect of Dabigatran Etexilate Capsules is available (see section 4.4).</p><p>Coagulation factor concentrates (activated or non-activated) or recombinant Factor VIIa may be taken into account. There is some experimental evidence to support the role of these medicinal products in reversing the anticoagulant effect of dabigatran, but data on their usefulness in clinical settings and also on the possible risk of rebound thromboembolism is very limited. Coagulation tests may become unreliable following administration of suggested coagulation factor concentrates. Caution should be exercised when interpreting these tests. Consideration should also be given to administration of platelet concentrates in cases where thrombocytopenia is present or long acting antiplatelet drugs have been used. All symptomatic treatment should be given according to the physician&#39;s judgement.</p><p>Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings.</p><p>As protein binding is low, dabigatran can be dialysed; there is limited clinical experience to demonstrate the utility of this approach in clinical studies (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antithrombotic, direct thrombin inhibitors, ATC code: B01AE07.</p><p>Mechanism of action&nbsp;</p><p>Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma.</p><p>Since thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of thrombus. Dabigatran also inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.</p><p>Pharmacodynamic effects&nbsp;</p><p>In-vivo and ex-vivo animal studies have demonstrated antithrombotic efficacy and anticoagulant activity of dabigatran after intravenous administration and of dabigatran etexilate after oral administration in various animal models of thrombosis.</p><p>There is a clear correlation between plasma dabigatran concentration and degree of anticoagulant effect based on phase II studies. Dabigatran prolongs the thrombin time (TT), ECT, and aPTT. The calibrated quantitative diluted TT (dTT) test provides an estimation of dabigatran plasma concentration that can be compared to the expected dabigatran plasma concentrations. When the calibrated dTT assay delivers a dabigatran plasma concentration result at or below the limit of quantification, an additional coagulation assay such as TT, ECT or aPTT should be considered<strong>.</strong></p><p>The ECT can provide a direct measure of the activity of direct thrombin inhibitors.</p><p>The aPTT test is widely available and provides an approximate indication of the anticoagulation intensity achieved with dabigatran. However, the aPTT test has limited sensitivity and is not suitable for precise quantification of anticoagulant effect, especially at high plasma concentrations of dabigatran. Although high aPTT values should be interpreted with caution, a high aPTT value indicates that the patient is anticoagulated.&nbsp;</p><p>In general, it can be assumed that these measures of anti-coagulant activity may reflect dabigatran levels and can provide guidance for the assessment of bleeding risk, i.e. exceeding the 90<sup>th</sup> percentile of dabigatran trough levels or a coagulation assay such as aPTT measured at trough (for aPTT thresholds see section 4.4, table 2) is considered to be associated with an increased risk of bleeding.</p><p>Steady state (after day 3) geometric mean dabigatran peak plasma concentration, measured around 2 hours after 220 mg dabigatran etexilate administration, was 70.8 ng/mL, with a range of 35.2-162 ng/mL (25<sup>th</sup>-75<sup>th</sup> percentile range).The dabigatran geometric mean trough concentration, measured at the end of the dosing interval (i.e. 24 hours after a 220 mg dabigatran dose), was on average 22.0 ng/mL, with a range of 13.0-35.7 ng/mL (25<sup>th</sup>-75<sup>th</sup> percentile range). In a dedicated study exclusively in patients with moderate renal impairment (creatinine clearance, CrCL 30-50 mL/min) treated with dabigatran etexilate 150 mg QD, the dabigatran geometric mean trough concentration, measured at the end of the dosing interval, was on average 47.5 ng/mL, with a range of 29.6 - 72.2 ng/mL (25<sup>th</sup>-75<sup>th</sup> percentile range).</p><p>In patients treated for prevention of VTEs after hip or knee replacement surgery with 220 mg dabigatran etexilate once daily,</p><p>&bull; the 90<sup>th</sup> percentile of dabigatran plasma concentrations was 67 ng/mL, measured at trough (20-</p><p>28 hours after the previous dose) (see section 4.4 and 4.9),</p><p>&bull; the 90<sup>th</sup> percentile of aPTT at trough (20-28 hours after the previous dose) was 51 seconds, which would be 1.3-fold upper limit of normal.</p><p>The ECT was not measured in patients treated for prevention of VTEs after hip or knee replacement surgery with 220 mg dabigatran etexilate once daily.</p><p>Clinical efficacy and safety&nbsp;</p><p>Ethnic origin&nbsp;</p><p>No clinically relevant ethnic differences among Caucasians, African-American, Hispanic, Japanese or Chinese patients were observed.</p><p>Clinical trials in Venous Thromboembolism (VTE) prophylaxis following major joint replacement surgery&nbsp;</p><p>In 2 large randomized, parallel group, double-blind, dose&ndash;confirmatory trials, patients undergoing elective major orthopaedic surgery (one for knee replacement surgery and one for hip replacement surgery) received Dabigatran Etexilate Capsules 75 mg or 110 mg within 1-4 hours of surgery followed by 150 mg or 220 mg daily thereafter, haemostasis having been secured, or enoxaparin 40 mg on the day prior to surgery and daily thereafter.&nbsp;</p><p>In the RE-MODEL trial (knee replacement) treatment was for 6&ndash;10 days and in the RENOVATE trial (hip replacement) for 28&ndash;35 days. Totals of 2,076 patients (knee) and 3,494 (hip) were treated respectively.</p><p>Composite of total VTE (including PE, proximal and distal DVT, whatever symptomatic or asymptomatic detected by routine venography) and all-cause mortality constituted the primary end-point for both studies. Composite of major VTE (including PE and proximal DVT, whatever symptomatic or asymptomatic detected by routine venography) and VTE-related mortality constituted a secondary end-point and is considered of better clinical relevance.</p><p>Results of both studies showed that the antithrombotic effect of Dabigatran Etexilate Capsules 220 mg and 150 mg were statistically non-inferior to that of enoxaparin on total VTE and allcause mortality. The point estimate for incidence of major VTE and VTE related mortality for the 150 mg dose was slightly worse than enoxaparin (table 6). Better results were seen with the</p><p>220 mg dose where the point estimate of Major VTE was slightly better than enoxaparin (table</p><p>6).</p><p>The clinical studies have been conducted in a patient population with a mean age &gt; 65 years.</p><p>There were no differences in the phase 3 clinical studies for efficacy and safety data between men and women.</p><p>In the studied patient population of RE-MODEL and RE-NOVATE (5,539 patients treated), 51 % suffered from concomitant hypertension, 9 % from concomitant diabetes, 9 % from concomitant coronary artery disease and 20 % had a history of venous insufficiency. None of these diseases showed an impact on the effects of dabigatran on VTE-prevention or bleeding rates.</p><p>Data for the major VTE and VTE-related mortality endpoint were homogeneous with regards to the primary efficacy endpoint and are shown in table 6.</p><p>Data for the total VTE and all cause mortality endpoint are shown in table 7.</p><p>Data for adjudicated major bleeding endpoints are shown in table 8 below.</p><p>Table 6: Analysis of major VTE and VTE-related mortality during the treatment period in the</p><p>RE-MODEL and the RE-NOVATE orthopaedic surgery studies</p><table border="0" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td style="vertical-align:top"><p>Trial</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dabigatran etexilate&nbsp;</p><p>220 mg</p></td><td style="vertical-align:top"><p>Dabigatran etexilate</p><p>150 mg</p></td><td style="vertical-align:top"><p>Enoxaparin</p><p>40 mg</p></td></tr><tr><td style="vertical-align:top"><p>RE-NOVATE (hip)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>909</p></td><td style="vertical-align:top"><p>888</p></td><td style="vertical-align:top"><p>917</p></td></tr><tr><td style="vertical-align:top"><p>Incidences (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>28 (3.1)</p></td><td style="vertical-align:top"><p>38 (4.3)</p></td><td style="vertical-align:top"><p>36 (3.9)</p></td></tr><tr><td style="vertical-align:top"><p>Risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ratio</p></td><td style="vertical-align:top"><p>over</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>enoxaparin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.78</p></td><td style="vertical-align:top"><p>1.09</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95 % CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.48, 1.27</p></td><td style="vertical-align:top"><p>0.70, 1.70</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RE-MODEL (knee)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>506</p></td><td style="vertical-align:top"><p>527</p></td><td style="vertical-align:top"><p>511</p></td></tr><tr><td style="vertical-align:top"><p>Incidences (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13 (2.6)</p></td><td style="vertical-align:top"><p>20 (3.8)</p></td><td style="vertical-align:top"><p>18 (3.5)</p></td></tr><tr><td style="vertical-align:bottom"><p>Risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ratio</p></td><td style="vertical-align:bottom"><p>over</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>enoxaparin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.73</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95 % CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.36, 1.47</p></td><td style="vertical-align:top"><p>0.58, 2.01</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Table 7: Analysis of total VTE and all cause mortality during the treatment period in the RENOVATE and the RE-MODEL orthopaedic surgery studies</p><table border="0" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td style="vertical-align:top"><p>Trial</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dabigatran etexilate</p><p>220 mg</p></td><td style="vertical-align:top"><p>Dabigatran etexilate</p><p>150 mg</p></td><td style="vertical-align:top"><p>Enoxaparin&nbsp;</p><p>40 mg</p></td></tr><tr><td style="vertical-align:top"><p>RE-NOVATE (hip)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>880</p></td><td style="vertical-align:top"><p>874</p></td><td style="vertical-align:top"><p>897</p></td></tr><tr><td style="vertical-align:top"><p>Incidences (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>53 (6.0)</p></td><td style="vertical-align:top"><p>75 (8.6)</p></td><td style="vertical-align:bottom"><p>60 (6.7)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ratio</p><p>enoxaparin</p></td><td style="vertical-align:top"><p>over</p></td><td style="vertical-align:top"><p>&nbsp;0.9</p></td><td style="vertical-align:top"><p>1.28</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95 % CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.63, 1.29)</p></td><td style="vertical-align:top"><p>(0.93, 1.78)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RE-MODEL (knee)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>503</p></td><td style="vertical-align:top"><p>526</p></td><td style="vertical-align:top"><p>512</p></td></tr><tr><td style="vertical-align:top"><p>Incidences (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>183 (36.4)</p></td><td style="vertical-align:top"><p>213 (40.5)</p></td><td style="vertical-align:bottom"><p>193 (37.7)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Risk &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ratio</p><p>enoxaparin</p></td><td style="vertical-align:top"><p>over</p></td><td style="vertical-align:top"><p>&nbsp;0.97</p></td><td style="vertical-align:top"><p>1.07</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>95 % CI</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(0.82, 1.13)</p></td><td style="vertical-align:top"><p>(0.92, 1.25)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Table 8: Major bleeding events by treatment in the individual RE-MODEL and the RE-</p><p>NOVATE studies</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_45209" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:471.75pt;height:213pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="629" height="284" alt="" vspace="0" hspace="0" border="0" style="width:629px;height:284px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Dabigatran Etexilate Capsules in all subsets of the paediatric population in prevention of thromboembolic events for the granted indication (see section 4.2 for information on paediatric use).</p><p>Clinical trials for the prevention of thromboembolism in patients with prosthetic heart valves A phase II study examined dabigatran etexilate and warfarin in a total of 252 patients with recent mechanical valve replacement surgery (i.e. within the current hospital stay) and in patients who received a mechanical heart valve replacement more than three months ago. More thromboembolic events (mainly strokes and symptomatic/asymptomatic prosthetic valve thrombosis) and more bleeding events were observed with dabigatran etexilate than with warfarin. In the early post-operative patients, major bleeding manifested predominantly as haemorrhagic pericardial effusions, specifically in patients who started dabigatran etexilate early (i.e. on Day 3) after heart valve replacement surgery (see section 4.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration, dabigatran etexilate is rapidly and completely converted to dabigatran, which is the active form in plasma. The cleavage of the prodrug dabigatran etexilate by esterasecatalysed hydrolysis to the active principle dabigatran is the predominant metabolic reaction. The absolute bioavailability of dabigatran following oral administration of Dabigatran Etexilate Capsules was approximately 6.5 %.</p><p>After oral administration of Dabigatran Etexilate Capsules in healthy volunteers, the pharmacokinetic profile of dabigatran in plasma is characterized by a rapid increase in plasma concentrations with C<sub>max</sub> attained within 0.5 and 2.0 hours post administration.</p><p>Absorption&nbsp;</p><p>A study evaluating post-operative absorption of dabigatran etexilate, 1-3 hours following surgery, demonstrated relatively slow absorption compared with that in healthy volunteers, showing a smooth plasma concentration-time profile without high peak plasma concentrations. Peak plasma concentrations are reached at 6 hours following administration in a postoperative period due to contributing factors such as anaesthesia, gastrointestinal paresis, and surgical effects independent of the oral medicinal product formulation. It was demonstrated in a further study that slow and delayed absorption is usually only present on the day of surgery. On subsequent days absorption of dabigatran is rapid with peak plasma concentrations attained 2 hours after medicinal product administration.</p><p>Food does not affect the bioavailability of dabigatran etexilate but delays the time to peak plasma concentrations by 2 hours.</p><p>The oral bioavailability may be increased by 75 % after a single dose and 37 % at steady state compared to the reference capsule formulation when the pellets are taken without the Hydroxypropylmethylcellulose (HPMC) capsule shell. Hence, the integrity of the HPMC capsules should always be preserved in clinical use to avoid unintentionally increased bioavailability of dabigatran etexilate. Therefore, patients should be advised not to open the capsules and taking the pellets alone (e.g. sprinkled over food or into beverages) (see section</p><p>4.2).</p><p>Distribution&nbsp;</p><p>Low (34-35 %) concentration independent binding of dabigatran to human plasma proteins was observed. The volume of distribution of dabigatran of 60&ndash;70 L exceeded the volume of total body water indicating moderate tissue distribution of dabigatran.</p><p>C<sub>max</sub> and the area under the plasma concentration-time curve were dose proportional. Plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 11 hours in healthy elderly subjects. After multiple doses a terminal half-life of about 12-14 hours was observed. The half-life was independent of dose. Half-life is prolonged if renal function is impaired as shown in table 9.</p><p>Biotransformation&nbsp;</p><p>Metabolism and excretion of dabigatran were studied following a single intravenous dose of radiolabeled dabigatran in healthy male subjects. After an intravenous dose, the dabigatranderived radioactivity was eliminated primarily in the urine (85 %). Faecal excretion accounted for 6 % of the administered dose. Recovery of the total radioactivity ranged from 88-94 % of the administered dose by 168 hours post dose.&nbsp;</p><p>Dabigatran is subject to conjugation forming pharmacologically active acylglucuronides. Four positional isomers, 1-O, 2-O, 3-O, 4-O-acylglucuronide exist, each accounts for less than 10 % of total dabigatran in plasma. Traces of other metabolites were only detectable with highly sensitive analytical methods. Dabigatran is eliminated primarily in the unchanged form in the urine, at a rate of approximately 100 mL/min corresponding to the glomerular filtration rate. <u>Special populations</u>&nbsp;</p><p>Renal insufficiency&nbsp;</p><p>In phase I studies the exposure (AUC) of dabigatran after the oral administration of Dabigatran Etexilate Capsules is approximately 2.7-fold higher in volunteers with moderate renal insufficiency (CrCL between 30-50 mL/min) than in those without renal insufficiency.</p><p>In a small number of volunteers with severe renal insufficiency (CrCL 10-30 mL/min), the exposure (AUC) to dabigatran was approximately 6 times higher and the half-life approximately 2 times longer than that observed in a population without renal insufficiency (see sections 4.2, 4.3 and 4.4).</p><p>Table 9: Half-life of total dabigatran in healthy subjects and subjects with impaired renal function.</p><table border="0" cellspacing="0" cellpadding="0" style="width:664px"><tbody><tr><td style="vertical-align:top"><p>glomerular (CrCL,)</p><p>[mL/min]</p></td><td style="vertical-align:top"><p>filtration</p></td><td style="vertical-align:top"><p>rate</p></td><td colspan="2" style="vertical-align:top"><p>gMean (gCV%; range)&nbsp;</p><p>half-life&nbsp;</p><p>[h]&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 80</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>13.4 (25.7 %; 11.0-21.6)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 50-&lt; 80</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>15.3 (42.7 %;11.7-34.1)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 30-&lt; 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>18.4 (18.5 %;13.3-23.0)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>27.2(15.3 %; 21.6-35.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Additionally, dabigatran exposure (at trough and peak) was assessed in a prospective open label</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>randomized pharmacokinetic study in NVAF patients with severe renal impairment (defined as creatinine clearance [CrCl] 15-30 mL/min) receiving dabigatran etexilate 75 mg twice daily. This regimen resulted in a geometric mean trough concentration of 155 ng/ml (gCV of 76.9 %), measured immediately before administration of the next dose and in a geometric mean peak concentration of 202 ng/ml (gCV of 70.6 %) measured two hours after the administration of the last dose.</p><p>Clearance of dabigatran by haemodialysis was investigated in 7 patients with end-stage renal disease (ESRD) without atrial fibrillation. Dialysis was conducted with 700 mL/min dialysate flow rate, four hour duration and a blood flow rate of either 200 mL/min or 350-390 mL/min. This resulted in a removal of 50 % to 60 % of dabigatran concentrations, respectively. The amount of drug cleared by dialysis is proportional to the blood flow rate up to a blood flow rate of 300 mL/min. The anticoagulant activity of dabigatran decreased with decreasing plasma concentrations and the PK/PD relationship was not affected by the procedure.</p><p>Elderly patients&nbsp;</p><p>Specific pharmacokinetic phase I studies with elderly subjects showed an increase of 40 to 60 % in the AUC and of more than 25 % in C<sub>max</sub> compared to young subjects.</p><p>The effect by age on exposure to dabigatran was confirmed in the RE-LY study with an about 31 % higher trough concentration for subjects &ge; 75 years and by about 22 % lower trough level for subjects &lt; 65 years compared to subjects between 65 and 75 years (see sections 4.2 and 4.4).</p><p>Hepatic impairment&nbsp;</p><p>No change in dabigatran exposure was seen in 12 subjects with moderate hepatic insufficiency (Child Pugh B) compared to 12 controls (see sections 4.2 and 4.4).</p><p>Body weight&nbsp;</p><p>The dabigatran trough concentrations were about 20 % lower in patients with a body weight &gt; 100 kg compared with 50-100 kg. The majority (80.8 %) of the subjects were in the &ge; 50 kg and &lt; 100 kg category with no clear difference detected (see sections 4.2 and 4.4). Limited clinical data in patients &lt; 50 kg are available.</p><p>Gender&nbsp;</p><p>Active substance exposure in the primary VTE prevention studies was about 40 % to 50 % higher in female patients and no dose adjustment is recommended.</p><p>Ethnic origin&nbsp;</p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding dabigatran pharmacokinetics and pharmacodynamics.</p><p>Pharmacokinetic interactions&nbsp;</p><p>The pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter P-gp. Therefore concomitant use of P-gp transporter inhibitors (amiodarone, verapamil, clarithromycin, quinidine, dronedarone, ticagrelor and ketoconazole) and inducers (rifampicin) had been investigated (see sections 4.2, 4.4 and 4.5).</p><p>In vitro interaction studies did not show any inhibition or induction of the principal isoenzymes of cytochrome P450. This has been confirmed by in vivo studies with healthy volunteers, who did not show any interaction between this treatment and the following active substances: atorvastatin (CYP3A4), digoxin (P-gp transporter interaction) and diclofenac (CYP2C9)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>Effects observed in the repeat-dose toxicity studies were due to the exaggerated pharmacodynamics effect of dabigatran.</p><p>An effect on female fertility was observed in the form of a decrease in implantations and an increase in pre-implantation loss at 70 mg/kg (5-fold the plasma exposure level in patients). At doses that were toxic to the mothers (5- to 10-fold the plasma exposure level in patients), a decrease in foetal body weight and viability along with an increase in foetal variations were observed in rats and rabbits. In the pre- and post-natal study, an increase in foetal mortality was observed at doses that were toxic to the dams (a dose corresponding to a plasma exposure level 4-fold higher than observed in patients). In lifetime toxicology studies in rats and mice, there was no evidence for a tumorigenic potential of dabigatran up to maximum doses of 200 mg/kg.</p><p>Dabigatran, the active moiety of dabigatran etexilate Mesylate, is persistent in the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tartaric Acid USP-NF 100% pelletized (Tap&reg; 500), Hypromellose USP 2910, 5cps (Methocel E5 premium LV ), Talc USP (Luzenac Pharma),Isopropyl alcohol USP, Methylene Chloride USP-NF, Sugar Spheres USP/NF, Mesh 35-45 (355 - 500 MICRONS), Hydroxy propyl cellulose USP-NF (Klucel EXF) and Empty hard HPMC capsule shells, size &#39;1&#39;, cream opaque cap and cream opaque body, imprinted with &#39;H&#39; in black on cap and D16&#39; in black on body, IH</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.<strong> </strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Co. 
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia   
Tel: +966 11 477 2215
Manufacture: 
Hetero Lab Unit III, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug-2021. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>